1. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)
- Author
-
Sidney O'Bryant, Michael S. Rafii, Gabriela Muranevici, Dawn C. Matthews, Michael C. Donohue, Seth Ness, and Robert A. Rissman
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Down syndrome ,Neurofilament light ,Precuneus ,tau Proteins ,Neuropsychological Tests ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Alzheimer Disease ,Neurofilament Proteins ,Internal medicine ,medicine ,Humans ,Inverse correlation ,Amyloid beta-Peptides ,business.industry ,General Neuroscience ,Neurodegeneration ,Alzheimer's disease biomarkers ,Brain ,General Medicine ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Clinical Psychology ,030104 developmental biology ,medicine.anatomical_structure ,Posterior cingulate ,Positron-Emission Tomography ,Biomarker (medicine) ,Female ,Geriatrics and Gerontology ,Down Syndrome ,business ,030217 neurology & neurosurgery ,Biomarkers - Abstract
BACKGROUND Adults with Down syndrome (DS) are at very high risk for Alzheimer's disease (AD). Neurofilament light (NF-L) has emerged as a potential blood-based biomarker of neurodegeneration due to AD. OBJECTIVE To understand the relationship between plasma NF-L with age, brain amyloid, and tau pathology, neurodegeneration as well as cognitive and functional performance. METHODS We analyzed imaging data as well as cognitive measures in relation to plasma NF-L in adults with DS, ages 30 to 60 who were enrolled in the Down Syndrome Biomarker Initiative. RESULTS We found significant correlations between NF-L plasma concentrations and amyloid pathology (r = 0.73, p = 0.007, pa = 0.041) and significant inverse correlations with regional glucose metabolism in 5 of 6 regions examined, which were Anterior cingulate (r = -0.55, p = 0.067, pa = 0.067), Posterior cingulate r = -0.90, p
- Published
- 2019